Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Vistagen Therapeutics, Inc.
organization4 mentionslast seen Nov 9, 2026
Late clinical-stage biopharmaceutical company developing intranasal product candidates called pherines.
Relationships 7
- Vistagen Therapeutics, Inc.developsitruvone99% confidence4 sources
- Vistagen Therapeutics, Inc.developsrefisolone99% confidence4 sources
- Vistagen Therapeutics, Inc.developsfasedienol99% confidence4 sources
- Vistagen Therapeutics, Inc.developspherine99% confidence3 sources
- Vistagen Therapeutics, Inc.employsShawn K. Singh99% confidence3 sources
- Vistagen Therapeutics, Inc.employsAngel S. Angelov99% confidence2 sources
- Vistagen Therapeutics, Inc.employsShawn Singh97% confidence1 source
Relationship
Vistagen Therapeutics, Inc.employsShawn K. Singh
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 30, 2026Vistagen Therapeutics, Inc. 8-K: Item 2.05: Cost Associated with Exit or Disposal Activities; Item 8.01: Other Events
Shawn K. Singh President and Chief Executive Officer
- filingSEC EDGARSep 24, 2026Vistagen Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Shawn K. Singh President and Chief Executive Officer
- filingSEC EDGARSep 22, 2026Vistagen Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Shawn K. Singh, President and Chief Executive Officer